Answers are grounded in this paper and cite their sources.
Review uncovers the potential of probiotics in Alzheimer's disease treatment, suggesting new therapeutic strategies.
Alzheimer’s disease (AD) is the most common form of dementia, historically considered exclusively as a neurological condition treated primarily with cholinergic and glutamatergic inhibitors. Recent evidence highlights the significant influence of peripheral systems, particularly the gut-brain axis, on AD pathology. The gut microbiota plays a critical role in both physiological and psychological functions, and its interactions may impact the integrity of the blood-brain barrier, potentially contributing to neurodegenerative processes. Emerging therapeutic strategies targeting the gut microbiome, including both pharmacological and non-pharmacological approaches such as probiotics and prebiotics, offer promising avenues for intervention. This review synthesizes current literature and illustrative data to elucidate the connections among the gut-brain axis, neuroinflammation, and neuroprotection, and their implications for the pathogenesis and potential treatment of AD.
No takes yet. Share an insight, caveat, or question.
Medeiros et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: